Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
activityin, arm, breadth, Cert, CFO, condensed, DSMB, EMA, implantation, Incivek, invoiced, irrevocable, Kendall, larger, lt, maximum, median, middle, otherFlaviviridae, passed, perpetual, Person, placement, prevail, prominence, RB, reallocated, relinquish, retrospective, RVR, tablet, transparency, truncate, weaken
Removed:
accelerated, assuming, Baraclude, caption, cut, cutting, dipoxil, discounted, disoproxil, dissolved, Dr, EMEA, exacerbated, expended, fumerate, half, Hepsera, holder, indeterminate, InterMune, liquidating, Pfizer, plc, rating, receiver, relation, rental, rented, stability, strain, sublease, subleased, utility, Viread
Filing tables
Filing exhibits
Related press release
IDIX similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-118341, 333-128882, 333-143620 and 333-167330) and Form S-3 (File Nos. 333-127710, 333-129213, 333-153471, 333-159716, 333-173374 and 333-177167) of Idenix Pharmaceuticals, Inc. of our report dated March 6, 2012 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 6, 2012